Published in TZ Latest News
8 November, 2021 by The TZ Newswire Staff
Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01
HEIDELBERG, Germany and SANTA ANA, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) — Affimed N.V.
read more